GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » PS Ratio

Beijing Luzhu Biotechnology Co (HKSE:02480) PS Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Beijing Luzhu Biotechnology Co's share price is HK$25.65. Beijing Luzhu Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.00. Hence, Beijing Luzhu Biotechnology Co's PS Ratio for today is .

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's PS Ratio or its related term are showing as below:

HKSE:02480's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.69
* Ranked among companies with meaningful PS Ratio only.

Beijing Luzhu Biotechnology Co's Revenue per Sharefor the six months ended in Jun. 2024 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.00.

Back to Basics: PS Ratio


Beijing Luzhu Biotechnology Co PS Ratio Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co PS Ratio Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23
PS Ratio
- - -

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Beijing Luzhu Biotechnology Co's PS Ratio

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's PS Ratio falls into.



Beijing Luzhu Biotechnology Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Beijing Luzhu Biotechnology Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=25.65/0
=

Beijing Luzhu Biotechnology Co's Share Price of today is HK$25.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Luzhu Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Beijing Luzhu Biotechnology Co  (HKSE:02480) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Beijing Luzhu Biotechnology Co PS Ratio Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Luzhu Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is its Core Product.
Executives
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Zhang Yanping 2202 Interest of your spouse
Kong Jian 2101 Beneficial owner
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines